In 2025, over 2 million new cancer cases are expected in the US, leading to 618,000 deaths annually. The global oncology market is projected to hit $208.9 billion by 2025, with potential to exceed $900 billion by 2034. Investments in research and innovative treatments are on the rise.

Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are promising cancer biotech stocks with “Strong Buy” ratings. ELTX, with a market cap of $158 million, is up 92.7% YTD. Cellectis, valued at $140 million, boasts a 60% gain this year. Autolus, with a market cap of $670 million, develops CAR-T cell therapies.

Elicio Therapeutics (ELTX) is advancing its ELI-002 7P treatment for pancreatic cancer, with a pivotal Phase 2 trial ongoing. The company’s Q1 2025 R&D expenses were $7.8 million, net loss narrowed to $11.2 million, and financial position was bolstered with a $10 million senior secured note in Q2.

Cellectis (CLLS) reported a strong Q1 2025, with consolidated revenues hitting $12 million. The company’s partnership with AstraZeneca, involving a $140 million investment, is a key driver of growth. Analysts unanimously rate CLLS a “Strong Buy,” with a price target of $5.60.

Autolus Therapeutics (AUTL) focuses on CAR-T cell therapies for blood cancers. The company reported $9 million in net product revenue in Q1 2025, driven by its lead therapy, AUCATZYL. AUTL received European approval for AUCATZYL in July, reflecting positive regulatory developments. Analysts are bullish on AUTL, with a consensus “Strong Buy” rating and a target price of $9.84.

These three cancer biotech firms show potential for significant growth, backed by strong analyst ratings and ongoing research and development. With upcoming catalysts and partnerships, they could deliver substantial returns in the future.

Read more at Yahoo Finance: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings